We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-2.50 | -10.64% | 21.00 | 21.00 | 22.00 | 25.00 | 20.25 | 24.25 | 6,183,038 | 16:40:40 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 1.04M | -21.69M | -0.0832 | -2.58 | 56.02M |
Date | Subject | Author | Discuss |
---|---|---|---|
13/2/2024 14:43 | gooosed Thanks for that and would be good to get an update from Angle on progress with the Bioview collaboration. Regarding Artios and the DDR assay, by a process of elimination I believe that the clinical trial using Parsortix is the one in the link below. As you can see, it's been designed as a phase I/II trial. I don't know what the split in terms of number of patients is between phases I and II but the overall total is 250. Worth noting that the trial is looking at ART6043 as both a monotherapy and in combination with the PARP inhibitors Olaparib and Talazoparib. PARP inhibitors also target the DDR pathway and have become an established standard of care therapy in several cancers but patients can become resistant to the drug. Artios believes that ART6043 can be effective in those patients. Easy to appreciate in a randomised study such as this how useful it would be to be able to carry out regular biopsies to analyse in real time the impact of both drugs on a patients tumour. If Artios progress to the phase II and continue to use Parsortix it will mean that the assay has been successful and useful and will provide early validation of both the Parsortix system and Angle's ability to develop bespoke assays in the clinical trial setting. | bermudashorts | |
13/2/2024 13:28 | April last year Angle announced a CTC-based HER2 assay development partnership with Bioview & indicated that "The development phase is estimated to take around a year to complete". "Given the significant third-party interest in a new assay for quantitative HER2 analysis based on CTCs, ANGLE and BioView have agreed to allow for the inclusion of third parties in this project and its funding as we move into the commercialisation stage after the initial development work is complete. The parties are continuing to discuss strategic routes to market with potential corporate partners." This adds to the awaited Ovarian & Prostate updates. In addition to that the share presentation highlighted the fact that Artios were progressing their DNA Damage Response trial from Phase I to Phase II. It's entirely possible that this will mean further consumables are required. With a great deal going on - news flow over the coming weeks & months should be steady. | gooosed | |
13/2/2024 13:20 | Very encouraging to see ongoing support for AGL after the recent trader's spike. It's achievements are beginning to be properly recognised now and the share price is entering a new phase with significant upwards momentum. | spa362 | |
13/2/2024 13:16 | Bones, do your husband and kids a favour and buy some agl before it hits 30p | atmysignal | |
13/2/2024 11:49 | Boney trying to find the post where you called the drop from 80p. I can see plenty of post calling 30p after the event. | john henry | |
13/2/2024 11:49 | 20p today?Likely | atmysignal | |
13/2/2024 11:35 | AGL looking good for buying momentum to increase again as we move into the afternoon. Maybe last chance to buy under 20? | spa362 | |
13/2/2024 11:35 | John olwnry of time for fest to fall back. I wouldn't say calling it wornng from nearly 80p to under 40p is wrong wither while so many where expecting it to keep rising. You sound. A little bitter. Chart still points to lower for fest imo but we will see. Traders will be in and out and they neve fall. In a straight line. | bones698 | |
13/2/2024 11:26 | well Boney698 looks like you called DEST incorrect, thats another one to add to the growing list | john henry | |
13/2/2024 11:25 | Looks like it's going to pop | rb1947 | |
13/2/2024 11:21 | Buyers nippling again | rb1947 | |
13/2/2024 11:20 | Bones999 is a bitter ex employee. | rb1947 | |
13/2/2024 11:16 | Agree time is fast running out for the next cash raise to be called! | bones699 | |
13/2/2024 11:06 | Ahh ok. Thanks for clarifying. Did think the flip flop was a bit extreme in the time frame | rajraj b | |
13/2/2024 10:37 | Bones698 said that. Bones699 is the uneducated childish version of Bones698 | zeus19 | |
13/2/2024 09:39 | Looks like yesterday's buyers still not finished :( Ho hum mistimed this one. | boris cobaka | |
13/2/2024 09:38 | 24 hours ago, you said this was set to fly. You've changed your tune. | rajraj b | |
13/2/2024 09:31 | Oh Dear! How annoying. | boris cobaka | |
13/2/2024 09:20 | Whens the next cash raise the piggy bank must be down to its last few coins to keep the lights on! | bones699 | |
13/2/2024 09:18 | Better still I can stay here watching the paint dry 😆 lol! | bones699 | |
12/2/2024 22:06 | Hang on though the interviewer Will likely ask: so alias Bones699, what do you do in your spare time? Well I sit in my bedroom/home office and post drivel on a bulletin board. I'm really sad.Interview terminated | muffster | |
12/2/2024 21:42 | Go and spend some time with your husband and kids.This beauty has turned and will motor north this month.Life is passing you by, move on with your life. You are employable if you just sort your head out and move on from Angle. | atmysignal | |
12/2/2024 16:31 | Very solid performance today. More tomorrow? | spa362 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions